{"transactions":[{"id":1087181,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2025-07-15T20:22:52.000Z","date":"2025-07-11","kind":"grant","planned":false,"acquired":true,"shares":60100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":60100,"derivative":{"exercise_price":0.59,"expiration_date":"2035-07-11","underlying":"Common Stock","underlying_shares":60100},"source":{"system":"sec-edgar","filing":"0001641172-25-019729","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000164117225019729/ownership.xml","form_type":"4"}},{"id":1451614,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2024-07-19T01:35:12.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":715,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option disclosed on this Form 4 was not previously reported due to an administrative oversight."},{"field":"shares","element":"transactionShares","label":"F2","text":"Share and dollar amounts give effect to the issuer's 1-for-35 reverse stock split effectuated on December 4, 2023, and 1-for-10 reverse stock split effectuated on April 25, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests annually in three equal installments commencing on May 24, 2024."}],"balance_after":715,"derivative":{"exercise_price":152.46,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":715},"source":{"system":"sec-edgar","filing":"0001493152-24-028405","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315224028405/ownership.xml","form_type":"4"}},{"id":2079330,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-12-20T21:00:18.000Z","date":"2022-12-16","kind":"grant","acquired":true,"shares":3000,"price":2.8815,"value":8644.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.78 to $2.97 per share,\ninclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission,\nupon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":44585,"source":{"system":"sec-edgar","filing":"0001493152-22-035985","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035985/ownership.xml","form_type":"4"}},{"id":2086041,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Warrant (right to buy)","published_at":"2022-12-15T00:37:39.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":11763,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The warrant is immediately exercisable in full."}],"balance_after":11763,"derivative":{"exercise_price":11.58,"expiration_date":"2023-10-31","underlying":"Common Stock","underlying_shares":11763},"source":{"system":"sec-edgar","filing":"0001493152-22-035487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035487/ownership.xml","form_type":"4"}},{"id":2086040,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Warrant (right to buy)","published_at":"2022-12-15T00:37:39.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":18058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The warrant is immediately exercisable in full."}],"balance_after":18058,"derivative":{"exercise_price":6.9,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":18058},"source":{"system":"sec-edgar","filing":"0001493152-22-035487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035487/ownership.xml","form_type":"4"}},{"id":2086039,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-15T00:37:39.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":21840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests in 3 equal annual installments commencing on January 28, 2023."}],"balance_after":21840,"derivative":{"exercise_price":16.36,"expiration_date":"2032-01-28","underlying":"Common Stock","underlying_shares":21840},"source":{"system":"sec-edgar","filing":"0001493152-22-035487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035487/ownership.xml","form_type":"4"}},{"id":2086038,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-15T00:37:39.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":21840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests in 3 equal annual installments commencing on February 8, 2022."}],"balance_after":21840,"derivative":{"exercise_price":16.36,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":21840},"source":{"system":"sec-edgar","filing":"0001493152-22-035487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035487/ownership.xml","form_type":"4"}},{"id":2086037,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-15T00:37:39.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":39708,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020."}],"balance_after":39708,"derivative":{"exercise_price":11.58,"expiration_date":"2029-04-02","underlying":"Common Stock","underlying_shares":39708},"source":{"system":"sec-edgar","filing":"0001493152-22-035487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035487/ownership.xml","form_type":"4"}},{"id":2086036,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-15T00:37:39.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":9927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the option is immediately exercisable. The option vested in 4 equal annual installments commencing on October 30, 2017."}],"balance_after":9927,"derivative":{"exercise_price":5.09,"expiration_date":"2027-10-30","underlying":"Common Stock","underlying_shares":9927},"source":{"system":"sec-edgar","filing":"0001493152-22-035487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035487/ownership.xml","form_type":"4"}},{"id":2086035,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-15T00:37:39.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":9927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on October 21, 2016."}],"balance_after":9927,"derivative":{"exercise_price":5.09,"expiration_date":"2025-10-21","underlying":"Common Stock","underlying_shares":9927},"source":{"system":"sec-edgar","filing":"0001493152-22-035487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035487/ownership.xml","form_type":"4"}},{"id":2086034,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-12-15T00:37:39.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":41585,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation (\"Larkspur\") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the \"Business Combination Agreement\") by and among ZyVersa Therapeutics, Inc., a Florida corporation (\"Old ZyVersa\"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur (\"Merger Sub\") pursuant to which Merger Sub merged with and into Old ZyVersa (the \"Acquisition Merger\"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer."}],"balance_after":41585,"source":{"system":"sec-edgar","filing":"0001493152-22-035487","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035487/ownership.xml","form_type":"4"}}]}